MindWalk Unveils B Cell Llama™ Nanobody Discovery Platform, Backed by Peer-Reviewed Study
HYFT has more than doubled off its 52-week low of $0.316.
Summary
MindWalk Holdings Corp. launched B Cell Llama™, a new nanobody discovery platform for bispecific and cell therapies, validated by a peer-reviewed study and leveraging their AI technology.
Key Events · Product Development and Regulatory · HYFT
-
New Nanobody Discovery Platform
MindWalk introduced B Cell Llama™, a platform for discovering VHH nanobodies, which are critical for bispecific antibodies and cell therapies.
-
Peer-Reviewed Validation
The platform's capabilities are supported by a study in ACS Biomacromolecules, demonstrating amplified potency, ability to defeat resistance, and a potential immune-priming effect.
-
Strategic Market Focus
The platform targets the rapidly growing bispecific antibody and cell therapy markets, projected to reach US$50 billion by 2030.
-
AI Integration & IP Rights
B Cell Llama™ integrates with MindWalk's LensAI™ platform for AI-guided discovery, and the company holds first rights to commercialize jointly developed intellectual property.
Analysis · HYFT · Life Sciences
MindWalk Holdings Corp., a bio-native AI company, announced the launch of B Cell Llama™, a new platform for discovering VHH nanobodies. This platform is designed to address the rapidly growing markets for bispecific antibodies and cell therapies, projected to reach US$50 billion by 2030. The announcement is supported by a peer-reviewed study in ACS Biomacromolecules, which demonstrated enhanced potency, resistance-defeating modularity, and a potential immune-priming effect of VHH nanobodies. For a company of MindWalk's size, this new platform, coupled with their LensAI™ technology and first right to commercialize jointly developed IP, represents a significant strategic advancement that could drive future partnerships and pipeline development.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HYFT was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.8M. The 52-week trading range was $0.32 to $3.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.